EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering
February 1, 2021 4:04 PM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market... More
After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
January 27, 2021 6:05 PM ESTAfter-Hours Movers
AMC Entertainment Holdings, Inc. (NYSE: AMC) 25.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 9% HIGHER; Cantor Fitzgerald initiates with an Overweight rating and price target of $22.00.
Accelerate... More
Cantor Fitzgerald Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Overweight
January 27, 2021 4:03 PM ESTCantor Fitzgerald analyst Jennifer Kim initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with an Overweight rating and price target of $22.00.
The analyst comments "We are initiating coverage of EYPT shares with an Overweight rating and a 12-month PT of $22 using DCF analysis.... More
